Featured

MIA's Justin Karter interviews two leaders of the Task Force on Diagnostic Alternatives, a group of mental health professionals who have issued an open letter demanding a new look at psychiatric diagnosis.

An interview with Professor John Read who joins us to discuss the UK licensing of esketamine nasal spray (Spravato) for so-called ‘Treatment Resistant Depression’. John led a group of 12 academics and professionals who wrote to the UK regulator expressing concerns.

It took me a long time to realise that I was being gaslighted. In fact, I had no word to describe the experience until years after I had finally escaped, when I came across the term by chance. What is worse, whenever I talk about my past relationship now with friends in my new life, I am horrified to discover how common manipulative relationships are.

The UK’s Medicines & Healthcare Products Regulatory Agency is refusing to respond to the concerns of psychiatrists, parliamentarians, patients and other experts about the impending licensing of the street drug ketamine as a treatment for depression.

What follows is a doctor-patient interaction that I hope will become more commonplace across psychiatric outpatient clinics.